Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-03-25
Target enrollment:
Participant gender:
Summary
This protocol is an open label, single arm, non-randomized, phase I / II clinical trial
investigating the use of pegylated interferon alpha-2a (peg-IFN-α, Pegasys®, Genentech) for
prevention of relapse in acute myeloid leukemia (AML) not in remission at the time of
allogeneic hematopoietic stem cell transplantation (HCT).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center